ArticleNature chemical biology2014
Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring.
Article in Nature chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed.
- Affinity-Activated Protein Switches for Modular and Signal-ON Detection of Small Molecules.Analytical chemistry · 2026Article
- Real-Life Application of a Point-of-Care Biosensor for Phenylalanine in Patients With Phenylketonuria.Journal of inherited metabolic disease · 2026Observational
- Article
- Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current Challenges.Therapeutic drug monitoring · 2026Review
- Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026Review
- Next-generation hybrid bioanalytical platforms and clinical integration of TDM technologies for precision monitoring to optimize last-resort antibiotic therapy.Frontiers in pharmacology · 2026Review
- Article
- Machine learning-integrated electrochemical sensing of ciprofloxacin for digital point-of-care therapeutic drug monitoring.Mikrochimica acta · 2025Article
- Buttressing ligand-binding pockets in de novo designed NTF2-like domains.Protein science : a publication of the Protein Society · 2025Article
- Ultrasensitive and long-lasting bioluminescence immunoassay for point-of-care viral antigen detection.Nature biomedical engineering · 2025Article
- Bioluminescence in Clinical and Point-of-Care Testing.Biosensors · 2025Review
- Vertical DNA Nanostructure Arrays: Facilitating Functionalization on Macro-Scale Surfaces.ACS nano · 2025Article
- Engineering modular and tunable single-molecule sensors by decoupling sensing from signal output.Nature nanotechnology · 2025Article
- PEGylated ATP-Independent Luciferins for Noninvasive High-Sensitivity High-Speed Bioluminescence Imaging.ACS chemical biology · 2025Article
- Biosensing strategies using recombinant luminescent proteins and their use for food and environmental analysis.Analytical and bioanalytical chemistry · 2024Review
- Opportunities and challenges in design and optimization of protein function.Nature reviews. Molecular cell biology · 2024Review
- Bioluminescent Systems for Theranostic Applications.International journal of molecular sciences · 2024Review
- Micro/nanofluidic device for tamsulosin therapeutic drug monitoring in patients with benign prostatic hyperplasia at point of care.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
- Bright Red Bioluminescence from Semisynthetic NanoLuc (sNLuc).ACS chemical biology · 2024Article
- Turning Antibodies into Ratiometric Bioluminescent Sensors for Competition-Based Homogeneous Immunoassays.ACS sensors · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For many drugs, finding the balance between efficacy and toxicity requires monitoring their concentrations in the patient's blood. Quantifying drug levels at the bedside or at home would have advantages in terms of therapeutic outcome and convenience, but current techniques require the setting of a diagnostic laboratory. We have developed semisynthetic bioluminescent sensors that permit precise measurements of drug concentrations in patient samples by spotting minimal volumes on paper and recording the signal using a simple point-and-shoot camera. Our sensors have a modular design consisting of a protein-based and a synthetic part and can be engineered to selectively recognize a wide range of drugs, including immunosuppressants, antiepileptics, anticancer agents and antiarrhythmics. This low-cost point-of-care method could make therapies safer, increase the convenience of doctors and patients and make therapeutic drug monitoring available in regions with poor infrastructure.
Indexed as
Identifiers
24907901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.